Evaluation of trimetallic Ru(II)- and Os(II)-Arene complexes as potential anticancer agents

Banothile C.E. Makhubela; Mervin Meyer; Gregory S. Smith

doi:10.1016/j.jorganchem.2014.08.034

Evaluation of trimetallic Ru(II)- and Os(II)-Arene complexes as potential anticancer agents

Banothile C.E. Makhubela, Mervin Meyer, Gregory S. Smith

Research output: Contribution to journal › Article › peer-review

32 Citations (Scopus)

Abstract

Schiff-base ligands, tris-2-(salicylaldimine ethyl)amine and tris-2-(2-pyridylimine ethyl)amine (1 and 2) were prepared and complexed to Ru(II) and Os(II) entities to form new trimetallic complexes (3-10). The complexes are air- and moisture-stable and have been characterized fully using elemental analysis, FT-IR and NMR spectroscopy as well as HR-ESI-TOF-MS spectrometry. Related mononuclear analogues (11-14) were also prepared via the Schiff-base condensation reaction of propyl amine and the appropriate aldehyde to form propysalicylaldimine and propyl-2-pyridylimine ligands. Upon complexation with the respective metal dimers, ([OsCl₂(p-cym)]₂ and [OsBr₂(p-cym)]₂) complexes (11-14) formed and were characterized by elemental analysis, NMR, FT-IR spectroscopy and mass spectrometry. The cytotoxicity of the trimetallic complexes (3-10) and their mononuclear analogues were established against human osteosarcoma (MG63), human ovarian (A2780cisR; cisplatin-resistant) cancer cells and model human non-cancerous cells (KMST6, fibroblast). All the complexes exhibited moderate to high anti-cancer activities and the most potent complexes were further evaluated for their ability to inhibit DNA topoisomerase I (Topo I) - an enzyme key to cellular genetic processes, such as DNA replication and transcription.

Original language	English
Pages (from-to)	229-241
Number of pages	13
Journal	Journal of Organometallic Chemistry
Volume	772-773
DOIs	https://doi.org/10.1016/j.jorganchem.2014.08.034
Publication status	Published - 1 Dec 2014
Externally published	Yes

Keywords

Cancer
Cytotoxicity
I
Ruthenium(II)-arenes and osmium(II)-arenes
Topoisomerase
Trimetallic

ASJC Scopus subject areas

Biochemistry
Physical and Theoretical Chemistry
Organic Chemistry
Inorganic Chemistry
Materials Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jorganchem.2014.08.034

Cite this

@article{210ab3af93f84546a8d97cd17a93a195,

title = "Evaluation of trimetallic Ru(II)- and Os(II)-Arene complexes as potential anticancer agents",

abstract = "Schiff-base ligands, tris-2-(salicylaldimine ethyl)amine and tris-2-(2-pyridylimine ethyl)amine (1 and 2) were prepared and complexed to Ru(II) and Os(II) entities to form new trimetallic complexes (3-10). The complexes are air- and moisture-stable and have been characterized fully using elemental analysis, FT-IR and NMR spectroscopy as well as HR-ESI-TOF-MS spectrometry. Related mononuclear analogues (11-14) were also prepared via the Schiff-base condensation reaction of propyl amine and the appropriate aldehyde to form propysalicylaldimine and propyl-2-pyridylimine ligands. Upon complexation with the respective metal dimers, ([OsCl2(p-cym)]2 and [OsBr2(p-cym)]2) complexes (11-14) formed and were characterized by elemental analysis, NMR, FT-IR spectroscopy and mass spectrometry. The cytotoxicity of the trimetallic complexes (3-10) and their mononuclear analogues were established against human osteosarcoma (MG63), human ovarian (A2780cisR; cisplatin-resistant) cancer cells and model human non-cancerous cells (KMST6, fibroblast). All the complexes exhibited moderate to high anti-cancer activities and the most potent complexes were further evaluated for their ability to inhibit DNA topoisomerase I (Topo I) - an enzyme key to cellular genetic processes, such as DNA replication and transcription.",

keywords = "Cancer, Cytotoxicity, I, Ruthenium(II)-arenes and osmium(II)-arenes, Topoisomerase, Trimetallic",

author = "Makhubela, {Banothile C.E.} and Mervin Meyer and Smith, {Gregory S.}",

year = "2014",

month = dec,

day = "1",

doi = "10.1016/j.jorganchem.2014.08.034",

language = "English",

volume = "772-773",

pages = "229--241",

journal = "Journal of Organometallic Chemistry",

issn = "0022-328X",

publisher = "Elsevier",

}

TY - JOUR

T1 - Evaluation of trimetallic Ru(II)- and Os(II)-Arene complexes as potential anticancer agents

AU - Makhubela, Banothile C.E.

AU - Meyer, Mervin

AU - Smith, Gregory S.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Schiff-base ligands, tris-2-(salicylaldimine ethyl)amine and tris-2-(2-pyridylimine ethyl)amine (1 and 2) were prepared and complexed to Ru(II) and Os(II) entities to form new trimetallic complexes (3-10). The complexes are air- and moisture-stable and have been characterized fully using elemental analysis, FT-IR and NMR spectroscopy as well as HR-ESI-TOF-MS spectrometry. Related mononuclear analogues (11-14) were also prepared via the Schiff-base condensation reaction of propyl amine and the appropriate aldehyde to form propysalicylaldimine and propyl-2-pyridylimine ligands. Upon complexation with the respective metal dimers, ([OsCl2(p-cym)]2 and [OsBr2(p-cym)]2) complexes (11-14) formed and were characterized by elemental analysis, NMR, FT-IR spectroscopy and mass spectrometry. The cytotoxicity of the trimetallic complexes (3-10) and their mononuclear analogues were established against human osteosarcoma (MG63), human ovarian (A2780cisR; cisplatin-resistant) cancer cells and model human non-cancerous cells (KMST6, fibroblast). All the complexes exhibited moderate to high anti-cancer activities and the most potent complexes were further evaluated for their ability to inhibit DNA topoisomerase I (Topo I) - an enzyme key to cellular genetic processes, such as DNA replication and transcription.

AB - Schiff-base ligands, tris-2-(salicylaldimine ethyl)amine and tris-2-(2-pyridylimine ethyl)amine (1 and 2) were prepared and complexed to Ru(II) and Os(II) entities to form new trimetallic complexes (3-10). The complexes are air- and moisture-stable and have been characterized fully using elemental analysis, FT-IR and NMR spectroscopy as well as HR-ESI-TOF-MS spectrometry. Related mononuclear analogues (11-14) were also prepared via the Schiff-base condensation reaction of propyl amine and the appropriate aldehyde to form propysalicylaldimine and propyl-2-pyridylimine ligands. Upon complexation with the respective metal dimers, ([OsCl2(p-cym)]2 and [OsBr2(p-cym)]2) complexes (11-14) formed and were characterized by elemental analysis, NMR, FT-IR spectroscopy and mass spectrometry. The cytotoxicity of the trimetallic complexes (3-10) and their mononuclear analogues were established against human osteosarcoma (MG63), human ovarian (A2780cisR; cisplatin-resistant) cancer cells and model human non-cancerous cells (KMST6, fibroblast). All the complexes exhibited moderate to high anti-cancer activities and the most potent complexes were further evaluated for their ability to inhibit DNA topoisomerase I (Topo I) - an enzyme key to cellular genetic processes, such as DNA replication and transcription.

KW - Cancer

KW - Cytotoxicity

KW - I

KW - Ruthenium(II)-arenes and osmium(II)-arenes

KW - Topoisomerase

KW - Trimetallic

UR - http://www.scopus.com/inward/record.url?scp=84908334995&partnerID=8YFLogxK

U2 - 10.1016/j.jorganchem.2014.08.034

DO - 10.1016/j.jorganchem.2014.08.034

M3 - Article

AN - SCOPUS:84908334995

SN - 0022-328X

VL - 772-773

SP - 229

EP - 241

JO - Journal of Organometallic Chemistry

JF - Journal of Organometallic Chemistry

ER -

Evaluation of trimetallic Ru(II)- and Os(II)-Arene complexes as potential anticancer agents

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this